KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Sales (2019 - 2025)

Royalty Pharma's Return on Sales history spans 7 years, with the latest figure at 0.57% for Q4 2025.

  • For Q4 2025, Return on Sales rose 1.0% year-over-year to 0.57%; the TTM value through Dec 2025 reached 0.56%, down 3.0%, while the annual FY2025 figure was 0.56%, 3.0% down from the prior year.
  • Return on Sales for Q4 2025 was 0.57% at Royalty Pharma, down from 0.73% in the prior quarter.
  • Across five years, Return on Sales topped out at 1.45% in Q2 2021 and bottomed at 1.08% in Q4 2022.
  • The 5-year median for Return on Sales is 0.47% (2022), against an average of 0.5%.
  • The largest annual shift saw Return on Sales crashed -117bps in 2022 before it skyrocketed 228bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.09% in 2021, then plummeted by -1257bps to 1.08% in 2022, then surged by 212bps to 1.2% in 2023, then plummeted by -53bps to 0.56% in 2024, then increased by 2bps to 0.57% in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Return on Sales are 0.57% (Q4 2025), 0.73% (Q3 2025), and 0.16% (Q2 2025).